News

The MESO-BRAIN consortium has received a prestigious award of €3.3 million in funding from the European Commission as part of its Future and Emerging Technology (FET) scheme.

University of Pennsylvania scientists show that DNA “scrunching” may be responsible for driving DNA into a virus during replication.

Company has announced the start of a phase II clinical trial for Debio 1143 in combination with standard of care Carboplatin and Paclitaxel in Epithelial Ovarian Cancer.

Communesins, originally found in fungus, could hold potential as cancer drugs.

Company has announced its collaboration with Neurexpert Ltd to provide of advanced cell-based discovery services.

The company claims that APR-246 can be successfully combined with standard chemotherapy for ovarian cancer with minimal additional toxicity.

Particle Metrix report on the work of the Giebel Working Group on the Developmental Biology of Stem Cells in the Institute for Transfusion Medicine at the University Hospital of Duisburg-Essen.

Cellectricon and Neurexpert will co-promote their combined CNS drug discovery expertise, with a particular focus on synaptic function assays, for research into treatments of central nervous system disorders in the fields of psychiatry, neurology, pain and neurodegeneration.

Study highlights biopharma industry's current and future growth drivers.

Bristol-Myers Squibb and The University of Texas MD Anderson Cancer Center have announced a new clinical research collaboration to evaluate innovative strategies for the potential use of Bristol-Myers Squibb’s immuno-oncology (I-O) agents Opdivo (nivolumab) and Yervoy (ipilimumab) to treat early- and advanced-stage lung cancer patients.